NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy

Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial. Read more here.